基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
过继性自然杀伤(NK)细胞疗法是治疗三阴性乳腺癌的一种有前景的策略,但其疗效往往受到瘤内持久性差以及在免疫抑制性肿瘤微环境中功能耗竭的限制。
英文原题:Bone Marrow Mesenchymal Stem Cell-Mediated Radiosensitive Promoter-Combined Sodium Iodide Symporter for the Treatment of Breast Cancer.
Bone Marrow Mesenchymal Stem Cell-Mediated Radiosensitive Promoter-Combined Sodium Iodide Symporter for the Treatment of Breast Cancer.
构建携带放疗基因的基因工程化骨髓间充质干细胞(BMSCs),以靶向三阴性乳腺癌(TNBC),并评估肿瘤微环境中辐射损伤的疗效。
构建携带放疗基因的基因工程化骨髓间充质干细胞(BMSCs)以靶向三阴性乳腺癌(TNBC),并评估肿瘤微环境中辐射损伤的疗效。通过慢病毒转染将早期生长反应蛋白1(Egr1)-人钠碘同向转运体(hNIS)基因转染至BMSCs,并通过定量逆转录聚合酶链反应评估表达水平。进行Transwell及成脂和成骨实验以确定转基因干细胞的靶向特性及成脂和成骨特征。通过碘摄取实验测定转基因干细胞的放射性碘摄取及外排特征。使用131I-SPECT成像确定靶向TNBC的特性并量化体内转基因干细胞的碘摄取。基于肿瘤样本的免疫组织化学和流式细胞术分析,以肿瘤生长、免疫细胞浸润和肿瘤侵袭终点来表征131I治疗对BMSCs的影响。BMSCs-Egr1-hNIS细胞在辐射诱导后大量表达hNIS,并被趋化吸引至TNBC肿瘤。BMSCs-Egr1-hNIS的碘摄取随诱导浓度和时间的增加而逐渐增加。当131I的诱导浓度>100 Ci/mL并持续36 h时,细胞中碘摄取率增加。在体外,放射性碘在20 min内迅速从细胞流出,但在体内,放射性碘丢失速率显著较慢,并持续超过24 h。131I治疗后,肿瘤生长受到抑制,白细胞浸润至肿瘤部位,侵袭相关细胞因子水平显著降低。BMSCs-Egr1-hNIS介导的131I治疗可实现精准靶向放疗,抑制肿瘤生长,促进免疫细胞向肿瘤部位浸润,并降低肿瘤细胞的侵袭和转移特性。
To develop genetically engineered bone marrow mesenchymal stem cells (BMSCs) that carries a radiotherapy gene to target triple-negative breast cancer (TNBC) and to evaluate the efficacy of radiation damage within the tumor microenvironment. The early growth response protein1 ( Egr1 )-human sodium iodide symporter ( hNIS ) gene was transfected into BMSCs by lentiviral transfection and the expression levels were evaluated by quantitative reverse transcription polymerase chain reaction. Transwell and adipogenesis and osteogenesis assays were performed to determine the targeting properties and adipogenic and osteogenic characteristics of the transgenic stem cells. The uptake of radioiodine and the efflux characteristics of the transgenic stem cells were determined by iodine uptake experiments. 131 I-SPECT imaging was used to determine the characteristics of targeting to TNBC and to quantify the iodine uptake of transgenic stem cells in vivo . The effects of 131 I treatment on BMSCs were characterized using tumor growth, immune cell infiltration, and tumor invasion endpoints based on immunohistochemistry and flow cytometry analysis of tumor samples. BMSCs- Egr1 - hNIS cells abundantly express hNIS after radiation induction and are chemotactically attracted to TNBC tumors. Iodine uptake of BMSCs- Egr1 - hNIS gradually increased with increasing induction concentrations and times. When the inductive concentration of 131 I was >100 Ci/mL and lasted for 36 h, the rate of iodine uptake in cells increased. In vitro , the radioiodine quickly flowed out from cells within 20 min but in vivo, the rate of radioiodine loss was significantly slower and occurred over 24 h. After 131 I therapy, tumor growth was inhibited, white blood cells infiltrated into tumor site and the levels of invasion-related cytokines significantly decreased. BMSCs- Egr1 - hNIS -mediated 131 I therapy can achieve precisely targeted radiotherapy to inhibit tumor growth, promote immune cell infiltration to the tumor sites, and reduce the invasiveness and metastasis characteristics of tumor cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。